Salmeterol is a long-acting b2-agonist, widely used as an inhaled treatment of asthma and chronic obstructive pulmonary disease. It has very high b2-affinity (log K D 28.95) and is very selective for the b2-adrenoceptor (1000-fold selectivity over the b1-adrenoceptor). This study used a mutagenesis approach to determine the exact amino acids in the human b2-adrenoceptor responsible for this very high selectivity. Wild-type b2-and b1-adrenoceptors, chimeric b2/b1-adrenoceptors, and receptors with single-point mutations were transfected into Chinese hamster ovary-K1 cells, and affinity and function were studied using [ ]cAMP accumulation. Extracellular loop 3 (and specifically amino acid K305) had the largest single effect by reducing salmeterol's affinity for the b2-adrenoceptor by 31-fold. H296 in transmembrane 6 also had a major effect (18-fold reduction in salmeterol affinity). Combining these, in the double mutant b2-H296K-K305D, reduced salmeterol's affinity by 275-fold, to within 4-fold of that of the b1-adrenoceptor, without affecting the affinity or selectivity of other b2-agonists (salbutamol, formoterol, fenoterol, clenbuterol, or adrenaline). Another important amino acid was Y308 in transmembrane 7, although this also affected the affinity and selectivity of other agonists. F194 in extracellular loop 2 and R304 in extracellular loop 3 also had minor effects. None of these mutations (including the double mutant b2-H296K-K305D) affected the efficacy or duration of action of salmeterol. This suggests that the high affinity and selectivity of salmeterol are due to specific amino acids within the receptor itself, but that the duration of action is at least in part due to other factors, for example lipophilicity.
Introduction
Salmeterol, a long-acting b2-agonist, is widely used as an inhaled treatment of asthma and chronic obstructive pulmonary disease because it improves symptoms and reduces hospital admissions (Johnson, 1995; Waldeck, 2002; Cazzola et al., 2012; Kew et al., 2014) . b2-agonists (e.g., salbutamol) were first developed in the 1960s (Brittain et al., 1968; Hartley et al., 1968) . By stimulating b2-adrenoceptors in the lungs, they mimic the action of adrenaline causing bronchodilation (Johnson, 1995) . However, these drugs (which also include fenoterol and clenbuterol) have the major disadvantage that they are short acting and therefore require frequent dosing in patients and do not control nocturnal asthma (Bradshaw et al., 1987; Ball et al., 1991; Jack, 1991; Johnson, 1995; Waldeck, 2002) . In the 1980s, long-acting b2-agonists were sought, and formoterol and salmeterol were subsequently developed. Salmeterol (which consists of salbutamol with a long side chain) ( Fig. 1 ) was developed by Glaxo Group Research in a program specifically designed to identify long acting b2-compounds (Bradshaw et al., 1987; Ball et al., 1991 , Jack, 1991 Johnson, 1995) , and its long duration of action was confirmed in patients (Ullman and Svedmyr, 1988) .
Ligand binding, affinity, efficacy, and selectivity have largely been ascribed to interactions occurring within the transmembrane (TM) domains of the b2-adrenoceptor. These conclusions followed mutagenesis studies (e.g., Dixon et al., 1987a; Strader et al., 1987; Dohlman et al., 1988; Marullo et al., 1990) , photoaffinity label techniques (e.g., Wong et al., 1988) , studies involving extra-and intracellular region deletions (Dixon et al., 1987b) , and recognition of the similarity of the b-adrenoceptors to rhodopsin (Dixon et al., 1986) . The b2-adrenoceptor receptor crystal structure also largely confirms these findings (Rasmussen et al., 2011; Katritch et al., 2013; Venkatakrishnan et al., 2013) . Frielle et al. (1988) examined ligand affinities at six b2-b1 chimeric receptors, and found that mutants involving TM4 had lower affinity for noradrenaline, thus concluding that TM4 was the main region for b-agonist selectivity. Marullo et al. (1990) also identified TM4 as contributing to agonist binding and selectivity. However, neither of these studies is definitive because each chimera contained several TM, EL, and intracellular loop changes, making it difficult to pinpoint the precise region involved. Isogaya et al. (1998 Isogaya et al. ( , 1999 ) therefore made different chimeras in which only one TM domain was changed and investigated TM1, TM2, and TM7 changes on ligand binding (Kikkawa et al., 1998) . They found that TM2 and TM7 were important in agonist and antagonist affinity (and thus b2/b1 selectivity) and pinpointed Y308 in TM7 as a major contributor to b2 affinity, including that of salmeterol. However, these chimeras also contained EL and intracellular loop changes in addition to the TM changes. Furthermore, the Y308 mutation did not explain all of the high selectivity of salmeterol, and thus there must be selective binding occurring elsewhere in the b2-adrenoceptor.
Salmeterol is considered to have its long duration of action by binding to an exosite on the b2-adrenoceptor. The side chain is thought to anchor the molecule to the receptor in one region (exocite), whereas the head group binds to and activates the receptor via the normal orthosteric site (Jack, 1991; Johnson, 1995; Clark et al., 1996; Coleman et al., 1996) . Studies have suggested that this exocite may be in TM4 (Green et al., 1996 (Green et al., , 2001 or TM6/7 (Rong et al., 1999) . Furthermore, Isogaya et al. (1998) suggested that it was the side chain, not the head group, that interacted with TM7. However, it is also recognized that salmeterol is very lipophilic and therefore partitions into the cell membrane, making washout of the drug problematic (Rhodes et al., 1992; Anderson et al., 1994; Johnson, 1995; Coleman et al., 1996; Sykes et al., 2014) . This makes it difficult to discriminate between long duration due to true exocite binding or long duration due to membrane partition , and therefore its long duration of action may indeed be partly due to both mechanisms (Rhodes et al., 1992; Rong et al., 1999) .
This study therefore aimed to identify the regions of the human b2-adrenoceptor responsible for the high-affinity binding of salmeterol. As the selectivity of salmeterol for the human b2-adrenoceptor is 1000-to 3000-fold greater than that for the human b1-adrenoceptor (and this is due to selective affinity, not selective efficacy; Baker, 2010) , a chimeric b2/b1 mutagenesis study was undertaken in which single TM or EL regions were examined in turn before progressing to single-point mutagenesis studies (Baker et al., 2014) .
Materials and Methods
Molecular biology reagents were from Promega (Madison, WI). Lipofectamine, OPTIMEM, pcDNA3.1, and Top 10F competent cells were from Life Technologies (Paisley, UK). The QuikChange mutagenesis kit was from Stratagene (La Jolla, CA), and fetal calf serum was from PAA Laboratories (Teddington, Middlesex, UK). M96W, K97G, M98R, T100E, F101Y, N103S, W105F  b2-EL2  T177E, H178S, Q179D, I182R, N183R, A186N, N187D, E188P, T189K, F194V  b2-EL3  Q299H, D300R, N301E, I303V, R304P, K305D  b2-TM1  I38L, V39L, S41A, A46L, F49A, T56V  b2-TM2  T73M, C77S, A85L, A92T, H93I, I94V, L95V  b2-TM3  F108L, I112V, V129L  b2-TM4   a   V152G, I153L, I154V, L155C, M156T, I159A, V160I, G162A, T164V, Q170L  b2-TM5  Q197R, I205V, V213C, V216A, S220L  b2-TM6  T281V, I291L, V292A, I294V, H296K, V297A, I298F  b2-TM7  E306R, V307L, Y308F, I309V, L310F, L311F, I314L, V317A, G320A, L324I b1-WT b1-N b1 but with full N terminus of the b2-see Materials and Methods for details  b1-EL1  W121M, G122K, R123M, E125T, Y126F, S128N, F130W  b1-EL2  E202T, S203H, D204Q, R207I, R208N, N211A, D212N, P213E, K214T, V219F  b1-EL3  H350Q, R351D, E352N, V354I, P355R, D356K  b1-TM1  L63I, L64V, A66S, L71A, A74F, V81T  b1-TM2  M98T, S102C, L110A, T117A, I118H, V119I, V120L  b1-TM3  L133F, V137I, L154V  b1-TM4  G177V, L178I, V179I, C180L, T181M, A184I, I185V, A187G, V189T, L195Q, W199Y  b1-TM5  R222Q, V230I, C238V, A241V, L245S  b1-TM6  V332T, L342I, A343V, V345I, K347H, A348V, F349I  b1-TM7  R357E, L358V, F359Y, V360I, F361L, F362L, L365I, A368V, A371G, I375L a Making the full change here, i.e., with Y174W, rendered the receptor nonfunctional (no binding and no functional responses). This chimera with 10 of the 11 amino acid substitutions was therefore used as the b2-TM4 mutant. UK). AG 50W-4X resin was from Bio-Rad (Hertfordshire, UK). All other reagents were from Sigma-Aldrich (Poole, Dorset, UK). Racemic ligands were used throughout.
Molecular Biology
The cDNA sequence encoding the wild-type (WT) human b1-adrenoceptor (b1-WT) in pJG3.6 was a gift of S. Rees (GlaxoSmithKline, Stevenage, UK). This cDNA was subcloned as a HindIII/XbaI fragment into pcDNA3.1, and the sequence was confirmed by DNA sequencing. The cDNA for the WT human b2-adrenoceptor (b2-WT) in pcDNA3.1 was obtained from the Missouri S&T cDNA Resource Centre (www.cdna.org). This cDNA was also subcloned as a HindIII/XbaI fragment into pcDNA3.1, and the sequence was confirmed by DNA sequencing. The mutations described in Table 1 were generated using QuikChange mutagenesis and BioLine PolyMate Additive for GC-rich templates (Baker et al., 2014) . After subcloning in Top 10F competent cells, each mutant b2-adrenoceptor cDNA was excised on HindIII/XbaI and subcloned into native pcDNA3.1 containing a neomycin selection marker. All mutations and sequences were confirmed by DNA sequencing using the School of Life Sciences Sequencing Facility.
To detect the most important areas of the b2-WT important for salmeterol interactions, we made point mutations in first the EL and second the TM regions of the receptor such that each EL or TM region resembled that of the b1-WT. Prediction of the EL and TM regions was performed using ExPASy topology prediction tools (www.expasy. org). For example, six-point mutations were made in b2-WT (I38L, V39L, S41A, A46L, F49A, T56V), which effectively converted the TM1 region of this receptor to that of the b1-WT. This chimeric receptor was called b2-TM1 (i.e., b2-adrenoceptor, but with TM1 of the b1-WT; Table 1 ). This was then replicated for each EL and TM region (Table 1) . A similar set of mutations was made starting with the b1-WT and creating chimeric receptors each with an EL or TM region of the human b2-WT (Table 1) . For the N-terminal swaps, a VspI site (ATTAAT) was introduced immediately downstream of the A66S (b1; TCATTA AT) or S41A (b2; GCATTAAT) mutations produced during phase 2 of the production of TM1 mutations (Table 1), which   TABLE 2 Affinity (log K D values) of b-adrenoceptor ligands for the b2-WT and b1-WT and receptors containing whole TM or EL changes (see Table 1 *P , 0.001. One-way analysis of variance with post hoc Newman-Keuls comparing values from the mutant receptors with those obtained from the b2-WT or the b1-WT. Thus, the log K D for salmeterol at the b2-EL2 is different from that obtained from the b2-WT with P , 0.001. Likewise, the log K D for salmeterol at the b1-EL3 is different from that obtained from the b1-WT with P , 0.001; # P , 0.001. One-way analysis of variance with post hoc Newman-Keuls comparing each value with all other values in this set. Thus, the log K D for salmeterol at b2-EL3 is different from that obtained for b2-WT, b2-N, b2-EL1, b2-EL2, b2-TM1, b2-TM2, b2-TM3, b2-TM4, b2-TM5, b2-TM6, and b2-TM7 with P , 0.001 in all cases.
TABLE 3
The ratios of affinity (given as fold change) compared with that obtained in the b2-WT or b1-WT receptors (data from Table 2) Numbers in Roman text are a decrease in affinity compared with their respective WT, and numbers in italics are an increase in affinity compared with their respective WT. Thus, salmeterol has an affinity of 1.5-fold more at b2-N than b2-WT but 162-fold less at b2-EL3 than b2-WT. The b2/b1 selectivity for the ligands in these stable cell lines is also given. Table 1 ). Following mutagenesis, each receptor DNA was digested with VspI, the fragments were purified, and the alternative N terminal sequences were ligated to give a b1-adrenoceptor with the full b2-adrenoceptor N terminus (b1-N) or a b2-adrenoceptor with the full b1-adrenoceptor N terminus (b2-N). These constructs were expressed in Chinese hamster ovary (CHO)-K1 cells, and stable cell lines were generated (see below and Baker et al., 2014) . Once important EL or TM regions for the interaction of salmeterol were identified, to determine which individual amino acids were involved, several single-point mutations and chimeric receptors were made (Table 1) , and these constructs were expressed transiently in CHO-K1 cells.
Cell Culture. All CHO cells were grown in Dulbecco's modified Eagle's medium nutrient mix F12 (DMEM/F12) containing 10% fetal calf serum and 2 mM L-glutamine in a 37°C humidified 5% CO 2 :95% air atmosphere.
Generation of Stable Cell Lines. CHO-K1 cells were transfected with the WT human b1-or b2-adrenoceptor, or one of the full EL region or TM domain chimeric receptors (total 24 cell lines) using lipofectamine and OPTIMEM and selected for 3 weeks using resistance to geneticin (1 mg/ml for the receptor). Single clones were identified by dilution cloning and expanded to generate stable cell lines. These cell lines were used to identify the EL or TM regions important for salmeterol interaction.
Generation of Transient Populations. For transiently transfected cells, the parent CHO-K1 cells were transfected, as above, on day 1; the transfection reagents were removed and replaced with media on day 2; the cells were plated into 48-or 96-well plates on day 3; and the experiments were performed on day 4. .8 nM were used. Propranolol (10 mM) was used to define nonspecific binding in all experiments. Receptor expression level was measured, and protein was determined by the method of Lowry et al. (1951) .
For attempts at measuring duration of receptor binding, cells were incubated with either competing ligand in the presence of a fixed concentration of [ 3 H]CGP 12177 for 2 hours as above (control plate), or competing ligand alone for 2 hours (duration plate). After 2 hours, the control plate was washed as above, whereas the duration plate was washed with 2 Â 200 ml warm media and [ 3 H]CGP 12177 alone was added to the wells (except nonspecific binding wells when propranolol was also added) and incubated for 2 hours. After this second 2-hour incubation, the plates were washed with cold phosphate-buffered saline and Microscint was added, as above. Total and nonspecific binding were determined in each plate, and, as the duration plate had more washes than the control plate (and thus more potential for cell loss), the data were normalized to the total and nonspecific binding values for each plate.
[ 3 H]cAMP Accumulation
Cells were grown to confluence in sterile, clear plastic, tissue culturetreated 48-well plates. Cells were prelabeled with [ 14 C]cAMP to determine column efficiency; Baker, 2010) . Isoprenaline (10 mM) was used to define the maximal response in each plate of each experiment.
Data Analysis
Whole-Cell Binding. The affinity of [ TABLE 5 The ratios of affinity (as fold change) for ligands in Table 4 compared with that obtained in the b2-WT or b1-WT receptors Numbers in Roman text are a decrease in affinity compared with WT, and numbers in italics are an increase in affinity compared with their respective WT. Thus, salmeterol has an affinity of 1.4-fold more at b1-EL2 than b1-WT but 129-fold less at b2-EL3 than b2-WT. The b2/b1 selectivity for the ligands in these transiently transfected cells is also given. The affinity of the other ligands was determined from competition binding. All data points were performed in triplicate, and each 96-well plate contained six determinations of total and nonspecific binding. A sigmoidal response curve was then fitted to the data using Graphpad Prism 2.01, and the IC 50 was then determined as the concentration required to inhibit 50% of the specific binding using equation 2. 
For the assessment of duration of binding, as the duration plate had more washes than the control plate and thus there was greater loss of cells from this plate, the sigmoidal concentration response curve for To give a relative measure of duration of action, the degree of rightward shift of the curve was noted.
[ 3 H]cAMP Accumulation Agonist Responses. Agonist responses were best described by a one-site sigmoidal concentration response curve using the following equation:
where E max is the maximum response, [A] is the agonist concentration, and EC 50 is the concentration of agonist that produces 50% of the maximal response. A 10 mM (maximal) isoprenaline concentration was included in each plate for each separate experiment to allow agonist responses to be expressed as a percentage of the maximum response to the full agonist isoprenaline for each experiment. Data points in the figures are presented as mean 6 S.E.M. of triplicate determinations from a single experiment. Salmeterol bound to the b2-WT receptor with high affinity (log K D 28.95) and to the b1-WT with low affinity (log K D 25.80), demonstrating its high b2 selectivity (1400-fold; Fig. 2A ; Tables 2 and 3 ). To determine the key regions of the b2-AR responsible for this very selective high affinity, the affinity of salmeterol was examined in mutations in which the N terminus was swapped over, or each EL or each TM region in turn was mutated such that it contained the amino acid residues of the human b1-AR (Table 1 ). The b2-EL3 mutant receptor (i.e., the b2-AR but with EL3 of the b1-AR) had the largest effect with a reduction in salmeterol affinity of 162-fold ( Fig. 2C; Tables 2 and 3) . Table 2 gives the actual affinity (K D ) values obtained, but the ratios of the affinities observed for the mutant receptors compared with the WT receptors (Table 3) provide an easier way of picking out the major differences. Several other regions were also identified that decreased salmeterol affinity: these were TM6 (38-fold), TM7 (24-fold), and EL2 (4.7-fold; Fig. 2 ; Tables 2 and 3 ). The b2-TM2 mutant also has a very small effect with a reduction in salmeterol affinity of 2.4-fold.
Results

Identification of the Regions in the Human
The affinities of three other b2-selective agonists were also examined at these WT and chimeric receptors to determine whether the receptor regions identified were specific to salmeterol. Although the b2-EL2 and b2-EL3 receptors also reduced salbutamol, formoterol, and fenoterol affinity, these changes were less marked than those with salmeterol, with the largest changes being a 3.5-fold reduction in formoterol affinity at b2-EL2 and 2.5-fold at b2-EL3 (Tables 2 and 3 ). For the TM regions, the reduction in agonist affinity in b2-TM6 appeared to be specific to salmeterol, whereas formoterol and fenoterol also TABLE 7 The ratios of affinity (as fold change) for ligands in Table 6 compared with that obtained in the b2-WT or b1-WT receptors Numbers in Roman text are a decrease in affinity compared with WT, and numbers in italics are an increase in affinity compared with their respective WT. Thus, salmeterol has an affinity of 1.2-fold more at b2-T281V than b2-WT but 41-fold less at b2-TM6 than b2-WT. The b2/b1 selectivity for the ligands in these transiently transfected cells is also given. Identification of Salmeterol's High-Affinity Binding Sites had reduced affinity in b2-TM7 (of 5.2-and 4.4-fold, respectively), although this once again was not as great as that seen for salmeterol. Interestingly, when the reverse chimeric receptors were examined (i.e., b1-parent receptor with EL and TM regions in turn mutated to that of the b2-adrenoceptor), the changes observed were not as great. The single biggest changes observed were for the EL3 mutation, in which b1-EL3 had a 2.8 reciprocal increase in salmeterol affinity (larger than that for the other agonists) and b1-TM7 had a 4.4-fold increase in salmeterol affinity (accompanied by an increase of formoterol and fenoterol affinity of 8.1-and 5.9-fold, respectively; Tables 2 and 3).
Salmeterol
It therefore appeared that b2-selective nature of salmeterol binding was due largely to amino acids in EL3 and TM6, with smaller and less salmeterol-specific contributions from the amino acids in EL2 and TM7. Given the very small nature of the TM2 effect (less than 3-fold), this region was not investigated further.
Identification of the Amino Acids Involved in the Extracellular Regions: [ 3 H]CGP 12177 Whole-Cell Binding in Transiently Transfected Cells. To determine exactly which amino acids were important in each region, the effect of individual single-point mutations was examined in each of the regions identified above-namely, EL2, EL3, TM6, and TM7. Thus, single amino acids of interest were mutated from that of the b2-WT to that of the b1-WT. Also, to check for salmeterol rather general b2-selective mutations, the ligands tested were increased to include two further b2-selective agonists, adrenaline and clenbuterol. For the b2-EL2, the first single amino acid change examined was F194V. The b2-F194V mutant receptor had a reduction in salmeterol affinity that was actually slightly greater than that of the whole EL swap ( Fig. 3B ; Tables 4 and 5 ). The other amino acid changes were assessed as two amino acid changes at a time, and no changes over that seen with F194V alone were observed; thus, the single-point mutations for the rest of EL2 were not examined individually (data not shown). Interestingly, b2-F194V caused a reduction in affinity for all six agonists examined. As seen in the stable cell lines, the reciprocal mutations (b1-EL2 and b1-F219V) did not restore salmeterol affinity. Thus, for the EL2, the single amino acid change of F194V in the b2-adrenoceptor caused a small reduction in affinity of all the agonists examined; however, the reduction in salmeterol affinity was the greatest.
Given the much larger effect of the EL3 changes, each amino acid mutation was examined individually. In this study, the mutation K305D caused the single biggest reduction in affinity of salmeterol of 31-fold ( Fig. 3D ; Table 4 and 5). Furthermore, this effect was far greater for salmeterol than any of the other ligands examined. Again, this is more easily picked out by looking at the affinity ratios shown in Table 5 . The next largest change in salmeterol affinity was from the mutation of the adjacent amino acid R304P, which resulted in a 3.7-fold decrease in salmeterol affinity ( Fig. 3C; Tables 4 and 5) . A double-mutant receptor was therefore made, b2-R304P-K305D, to examine whether these effects were additive. The resultant affinity for salmeterol was indeed lower at this double mutation than either amino acid change alone, decreasing salmeterol affinity to within 2-fold of that achieved by the Identification of Salmeterol's High-Affinity Binding Sites whole b2-EL3 swap (Tables 4 and 5 ). Once again, the reciprocal b1 mutations either individually or with the double b1-P355R-D356K did not restore salmeterol affinity (Tables 4 and 5) .
Finally, the effect of combining the two main extracellular loop (EL) region mutations (i.e., F194V from EL2 and K305D from EL3) was examined by making the double mutation b2-F194V-K305D. This again had a decrease in salmeterol affinity that was greater than either change alone, and once again the reciprocal b1 mutation (b1-V219F-D356K) did not restore salmeterol affinity (Tables 4 and 5) .
Identification of the Amino Acids Involved in the Transmembrane Regions: [ 3 H]CGP 12177 Whole-Cell Binding in Transiently Transfected Cells. From the stable cell line experiments above, TM6 and TM7 were identified as having significant effects on the affinity of salmeterol. Single-point mutations were therefore made in each of these domains to examine the effect of each amino acid in turn. In TM6, whereas V292A and I298F both had small effects on the affinity of salmeterol, the mutation H296K caused the largest single effect, reducing the affinity of salmeterol to within 2-fold of that of the whole TM6 change ( Fig. 4B ; Tables 6  and 7 ). For TM7, the mutation Y308F caused the single biggest decrease in the affinity of salmeterol ( Fig. 4C ; Tables 6 and 7 ). The whole TM7 mutation (b2-TM7) actually caused a significant decrease in affinity of several agonists, and the Y308F was the single biggest contributor to this for each ligand.
The effect of combining the two major TM mutations was also examined (i.e., H296K from TM6 and Y308F from TM7 in the double mutant b2-H296K-Y308F) and resulted in a further decrease in salmeterol affinity (Tables 6 and 7 ). The addition of Y308F to the K305D mutation (b2-K305D-Y308F) also reduced the affinity of salmeterol more than K305D alone (Tables 6 and 7) . Once again, the reciprocal b1 mutations (b1-K347H and b1-F359Y) either alone or in combination did not restore salmeterol affinity (Tables 6 and 7) .
Effect of Combining the Major EL Mutation with the Major TM Mutation: [ 3 H]CGP 12177 Whole-Cell Binding in Transiently Transfected Cells. Finally, the effect of the double mutation b2-H296K-K305D, which combines the major EL, salmeterol-specific mutation with the major TM, and salmeterol-specific mutation, was examined, and salmeterol affinity was reduced by 275-fold, to within 4-fold of that at the b1-WT ( Fig. 5 ; Tables 6 and 7) .
Effects of Different Amino Acids: [ 3 H]CGP 12177 Whole-Cell Binding in Transient Transfected Cells. To date, all of the single-point mutations had involved the change in amino acid from that found in the b2 to that found in the b1-adrenoceptor. The effect of other amino acid changes in these same residues was also assessed. The effect of changing the amino acids to alanine in the major EL regions (F194A, K305A) and the salmeterol-specific TM region (H296A) was examined (Tables 4-7) . Interestingly, the alanine in F194A reduced the affinity of salmeterol significantly more than the other compounds and thus produced a more salmeterol-specific change than that to the b1 amino acid V, whereas alanines at H296A and K305A had significantly less effect on the affinity of salmeterol than the K and D, respectively, from the b1-adrenoceptor. Also, the R304D mutation-i.e., moving the D one amino acid along to position 304-resulted in a salmeterolspecific reduction in affinity, but not as great as that seen for K305D. Furthermore, R304D was not able to produce any greater reduction in salmeterol affinity when K305 was also mutated to a glycine (b2-R304D-K305G).
Given that mutations at K305 had the single biggest and most selective effect on the affinity of salmeterol, the effect of changes to several different amino acids at this position was examined. This had differing effects, but the K305D mutation had the largest effect on the affinity of salmeterol (Tables 4 and 5) .
Duration of Action of Salmeterol. To attempt to measure the impact of these mutations on the duration of action of salmeterol, the binding assay was adapted to include a washout period. Thus, as detailed in Materials and Methods, cells were either incubated with the competing ligand and [ 3 H]CGP 12177 for 2 hours (control), or the competing ligand alone for 2 hours before this was removed by washing prior to the addition of [ 3 H]CGP 12177 alone for an additional 2 hours (duration; Fig. 6 ). Under these conditions, short-acting ligands should be washed away and the radioligand bind unopposed (shifting the curve to the right), whereas long-acting ligands should remain bound to the receptor after the washout period such that, following the addition of the radioligand, inhibition of radioligand binding would still occur. Salbutamol and fenoterol The measure of duration of binding is the log shift of the curve from the control curve to the duration curve run in parallel in each experiment. The log K D values for carvedilol are also given. The values are mean 6 S.E.M. for n separate experiments, and each separate n number has been obtained in a separate transiently transfected population of cells. Thus, salbutamol is short-acting in that the IC 50 of the binding curve is shifted more than 2 log units (100-fold) to the right following washout at all receptors. Carvedilol, however, is long-acting as the duration curve remains in a similar place to the control curve (and the shift in IC 50 is about 0). were identified as short-acting ligands at all receptors, and carvedilol was shown to be a long-acting ligand at all receptors ( Fig. 6 ; Table 8 ). The duration of salmeterol binding, however, remained relatively constant at all of the receptors ( Fig. 6 ; Table 8 ). This suggests that the duration of binding is not closely aligned to the receptor-ligand affinity and that salmeterol's long duration of action may be related to another property, for example, its lipophilicity, and thus ability to partition into the cell membrane, forming a reservoir for future receptor binding after the free ligand had been washed away. Fig. 7A ; Table 9 ). The salmeterol response was, however, considerably less potent (i.e., right-shifted) at b2-F194V, b2-K305D, and b2-H296K, and even more so in the double mutant b2-H296K-K305D ( Fig. 7 ; Table 9 ). Potency (EC 50 ) is, however, a complex measurement involving ligand affinity, receptor expression level, and tissue factors, as well as ligand efficacy (Johnson, 1995) . The ratio of K D /EC 50 (Table 10) , however, gives an indication of efficacy. The values obtained for the b2-WT (28.67/29.69) and b2-H296K- K305D (26.23/27.37) give K D /EC 50 ratios of 10 and 14, respectively, suggesting that salmeterol has similar efficacy at the two receptors.
Discussion
Salmeterol is widely used in the treatment of asthma and chronic obstructive pulmonary disease as a long-acting b2-agonist (Johnson, 1995; Waldeck, 2002; Cazzola et al., 2012; Kew et al., 2014) . It is one of the most selective b-ligands discovered; however, the mechanism for this remains controversial. This study determined where this extreme selectivity occurred using a mutagenesis approach.
To determine the receptor regions important for salmeterol binding, experiments were performed in cells expressing either the b1-WT, b2-WT, or a receptor in which either the N terminus, one EL, or TM domain had been mutated to that of the other receptor (Tables 1 and 2 ). The affinity and selectivity of salmeterol and three other agonists were studied-formoterol (long-acting, b2-selective agonist), salbutamol (short-acting, less b2-selective agonist from which salmeterol was developed), and fenoterol (short-acting agonist with some b2 selectivity; Jack, 1991; Johnson, 1995; Waldeck, 2002) . The b2-WT and b1-WT affinities and selectivities were very similar to previous reports (e.g., Isogaya et al., 1998 Isogaya et al., , 1999 Battram et al., 2006; Baker, 2010) . By comparing the ligand affinities at each mutant with that of the WT parent (Table 3) , EL3, TM6, TM7, and, to a lesser extent, EL2 were identified as important regions for salmeterol binding. TM7 and EL2 also affect other ligand affinities and were thus not salmeterol-specific. The equivalent b1 mutants did not recreate high-affinity salmeterol binding, although b1-TM7 had higher binding affinity for all ligands than b1-WT, again suggesting that TM7 has a more general role in b2/b1 affinity and selectivity. Others have previously demonstrated the importance of TM7 for ligand affinity (Isogaya et al., , 1999 Kikkawa et al., 1998) ; however, all of their TM7 mutants also involve EL3 changes. They also identified TM2 as affecting ligand affinity (although the TM2 chimeras also had EL changes), and, although there was a small TM2 effect noted in this work (2.4-fold), we did not investigate this further, as other regions appeared to have greater effects.
To determine the precise amino acids involved, single-point mutations were made in the b2-WT. Importantly, similar reductions in affinity and selectivity were seen in the stable cell lines and transient transfections (compare Tables 5 and 7 with  Table 3 ). Of these individual amino acid changes, b2-K305D from EL3 had the single biggest reduction in salmeterol affinity of 31-fold. Other major contributors to salmeterol affinity were H296K from TM6 (18-fold), Y308F from TM7 (11-fold), with more minor contributions from F194V from EL2 (5.6-fold), R304P from EL3 (3.7-fold), and possibly V292A from TM6 (3.0-fold).
Other ligands were also examined to determine whether these affinity changes were salmeterol-specific. Y308F reduced the formoterol affinity by 6-fold and fenoterol by 4-fold, and thus is important for several b2-ligands. This amino acid was identified by Isogaya et al. (1998 Isogaya et al. ( , 1999 , who also found reduced affinity of formoterol, procaterol, salmeterol, and TA-2005 (Kikkawa et al., 1998) . H296K, however, appeared to have little effect on the affinity of the other ligands, and thus was more salmeterol-specific. F194V and R304P from EL2 and EL3, respectively, were more minor, and thus the salmeterol-specific nature was more difficult to judge.
Thus, two amino acids were identified that affected salmeterol affinity in a specific manner, H296K and K305D, one that affected salmeterol and other ligand affinities, Y308F, and two with minor effects-F194Vand R304P.
As K305D had the single biggest loss of salmeterol affinity, dual mutations were made with this and the other important mutations. The double EL mutations of b2-R304P-K305D and b2-F194V-K305D decreased salmeterol affinity by 66-and 61-fold, respectively, suggesting that the minor effects of F194V and R304P have a small additive effect to the K305D mutation (Table 5 ). The effect of these double-mutant receptors on the Table 9 ) in both a log and normal scale providing an indication of efficacy Thus, from Table 9 salmeterol appears 10-fold less potent in b2-TM7 and b2-Y308F than at b2-WT, b2-V307L, and b2-I309V. However, when the effect of affinity is also taken into account (from Table 6 ), this change in potency is purely a measure of the change in affinity, and the apparent efficacy of salmeterol remains similar for all of these mutations. Identification of Salmeterol's High-Affinity Binding Sites other ligands was minimal with a potential borderline reduction of formoterol and adrenaline affinity (3-to 4-fold). The addition of Y308F to the salmeterol-specific mutations (b2-H296K-Y308F and b2-K305D-Y308F) decreased salmeterol affinity more than K305D and H296K alone (Table 7) , but small changes in affinity for formoterol and fenoterol were also seen. However, when the two greatest and most salmeterolspecific changes were combined (b2-H296K-K305D), the reduction in salmeterol affinity was 275-fold and within only 4-fold of the affinity for b1-WT. This double mutant had a borderline 3-fold effect on adrenaline affinity and no effect on the affinity of the other ligands, making it salmeterol specific. The effect of charge at position 305 was examined. The b2-amino acid lysine (K) is positively charged, whereas b1-aspartate (D) is negatively charged. Mutation to arginine (K305R), another positively charged amino acid with an exposed amine group, had little effect on salmeterol affinity (Table 4) . Likewise, glutamate (K305E), another negatively charged amino acid, retained lower salmeterol affinity. Histidine (K305H), which at physiologic pH would not be charged, resulted in loss of salmeterol affinity, as did the other noncharged amino acids glutamate, glycine, and serine (Table 4) . Thus, loss of the positive charge at position 305 affects the high affinity of salmeterol, potentially by disruption of a hydrogen bond to the oxygen in the side chain of salmeterol.
As affinity (K D ) is a measure of both how quickly a ligand associates with the receptor and how slowly it dissociates (K D 5 k off /k on ), dramatic affinity changes may cause significant changes in the duration of ligand action, and more specifically in the off rate. Attempts were therefore made to examine the duration of ligand action by incubating agonists and then removing the free ligand before the subsequent addition of (EL3), and Y308 (TM7) in the crystal structure of an agonist-bound, active state of a human b2-adrenoceptor-nanobody complex (Rasmussen et al., 2011) . This crystal structure was obtained with the agonist BI-167107 bound to a variant of the b2-adrenoceptor (where the third intracellular loop was replaced by T4 lysozyme) in complex with nanobody 80 (Rasmussen et al., 2011) . (B) Side and (C) top views of the b2-adrenoceptor (PDB ID 3POG; with the nanobody 80 sequence not included) reported by Rasmussen et al. (2011) were generated with Cn3D (National Centre for Biotechnology Information). The structure of BI-167107 is also shown. The position of residues H296, K305, and Y308 is shown in yellow.
[ 3 H]CGP 12177, and a right-shifted binding curve. Long-acting ligands should not dissociate from the receptor, and the curves should superimpose. Whereas fenoterol and salbutamol appeared as short-acting compounds, carvedilol was shown to have a very long duration of action ( Fig. 6 ; Table 8 ). The rank order of duration was carvedilol , salmeterol , formoterol , fenoterol and salbutamol, in keeping with previous studies (Bradshaw et al., 1987; Ball et al., 1991; Johnson, 1995) .
However, a long duration of action may be a consequence of a long residence time on the receptor itself or, for the case of lipophilic ligands, partitioning into the lipophilic membrane (Rhodes et al., 1992; Anderson et al., 1994; Coleman et al., 1996; Sykes et al., 2014) . Salmeterol had equal duration of action across all the receptors, despite large differences in affinity. Rebinding to the receptor of salmeterol that had previously partitioned into the membrane and therefore not removed by washing would prolong the apparent receptor residence time and mask changes in the duration of action at the receptor itself (Vauquelin, 2010; Vauquelin and Charlton, 2010; Sykes et al., 2014) . This would also apply to previous studies that observed a long duration of action of salmeterol (e.g., Bradshaw et al., 1987; Ball et al., 1991; Coleman et al., 1996) .
Finally, the impact of the mutations on ligand efficacy was examined by measuring [ 3 H]cAMP. Formoterol was consistently a full agonist (∼100% of isoprenaline maximum; Table 9 ), whereas salbutamol and salmeterol were both partial agonists (as in previous studies; Johnson, 1995; Coleman et al., 1996; Baker, 2010; Cazzola et al., 2012) . Salmeterol stimulated a partial agonist response at b2-H296K-K305D (78.1% of the isoprenaline maximum), which was very similar to that from b2-WT (74.7%) despite the large difference in log EC 50 values (27.37 versus 29.69, respectively; Table 9 ). There was no dramatic decrease in the degree of partial agonism for salmeterol, or change in K D /EC 50 ratio (Table 10 ), suggesting that the mutations did not affect salmeterol efficacy.
Advances have been made in the understanding of structure-activity relationships following the determination of the crystal structure of the human b2-adrenoceptor (Katritch et al., 2013; Venkatakrishnan et al., 2013) . Following early work on inactive mutated receptors bound by inverse agonists, recent crystal structures include agonistbound b2-adrenoceptors (Rosenbaum et al., 2011) or nanobodystabilized b2-adrenoceptor active states (Rasmussen et al., 2011) . Figure 8 shows the crystal structure of the human b2-adrenoceptor-T4 lysozyme construct in complex with nanobody 80 and the high affinity agonist BI167107 (Rasmussen et al., 2011) with residues K305, Y308, and H296 highlighted in yellow. All three residues are facing inward, toward the binding pocket at the top of TM6 and TM7 with K305 located in a key position between EL3 and TM7 (Fig. 8) , and are thus located in an important position for determining receptor-ligand interactions.
In conclusion, salmeterol is a highly b2-selective ligand that specifically binds to H296K in TM6 and K305D in EL3. Combining these (b2-H296K-K305D) reduces salmeterol affinity by 275-fold, to within 4-fold of that of the b1-WT, without affecting the affinity of other agonists. Another important, although less salmeterol-specific, amino acid is Y308F in TM7. F194V in EL2 and R304P in EL3 have minor effects. These mutations (including b2-H296K-K305D) do not affect the efficacy of salmeterol.
